John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital, Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Magee, Mitchell J., John H. Alexander, Gail Hafley, T Bruce Ferguson, C Michael Gibson, Robert A. Harrington, Eric D. Peterson, et al. “Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV.” Ann Thorac Surg 85, no. 2 (February 2008): 494–99. https://doi.org/10.1016/j.athoracsur.2007.10.008.

PMID
18222251
Full Text

Olenchock, Stephen A., Dimitri Karmpaliotis, William J. Gibson, Sabina A. Murphy, Matthew C. Southard, Lauren Ciaglo, Jacqueline Buros, et al. “Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters.” Ann Thorac Surg 85, no. 2 (February 2008): 520–24. https://doi.org/10.1016/j.athoracsur.2007.10.061.

PMID
18222256
Full Text

Harrington, R. A., J. H. Alexander, J. S. Hochman, H. R. Reynolds, V. Dzavik, and F. J. Van De Werf. “Tilarginine in patients with acute myocardial infarction and cardiogenic shock - In reply [7].” Journal of the American Medical Association 298, no. 9 (September 5, 2007): 972–73. https://doi.org/10.1001/jama.298.9.972.

Full Text

Cohen, Marc, Deepak L. Bhatt, John H. Alexander, Gilles Montalescot, Christoph Bode, Timothy Henry, Jean-Francois Tamby, et al. “Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.” Circulation 115, no. 20 (May 22, 2007): 2642–51. https://doi.org/10.1161/CIRCULATIONAHA.106.653428.

PMID
17502577
Full Text

Dzavík, Vladimir, Gad Cotter, Harmony R. Reynolds, John H. Alexander, Krishnan Ramanathan, Amanda L. Stebbins, David Hathaway, et al. “Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study.” Eur Heart J 28, no. 9 (May 2007): 1109–16. https://doi.org/10.1093/eurheartj/ehm075.

PMID
17459901
Full Text

TRIUMPH Investigators, Judith S., John H. Alexander, Harmony R. Reynolds, Amanda L. Stebbins, Vladimir Dzavik, Robert A. Harrington, Frans Van de Werf, and Judith S. Hochman. “Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial.” Jama 297, no. 15 (April 18, 2007): 1657–66. https://doi.org/10.1001/jama.297.15.joc70035.

PMID
17387132
Full Text

Gheorghiade, Mihai, Marvin A. Konstam, John C. Burnett, Liliana Grinfeld, Aldo P. Maggioni, Karl Swedberg, James E. Udelson, et al. “Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.” Jama 297, no. 12 (March 25, 2007): 1332–43. https://doi.org/10.1001/jama.297.12.1332.

PMID
17384438
Full Text

Goyal, Abhinav, John H. Alexander, Gail E. Hafley, Stacy H. Graham, Rajendra H. Mehta, Michael J. Mack, Randall K. Wolf, et al. “Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.” Ann Thorac Surg 83, no. 3 (March 2007): 993–1001. https://doi.org/10.1016/j.athoracsur.2006.10.046.

PMID
17307447
Full Text

Mahaffey, Kenneth W., Matthew T. Roe, Rakhi Kilaru, John H. Alexander, Frans Van de Werf, Robert M. Califf, Maarten L. Simoons, Eric J. Topol, and Robert A. Harrington. “Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials.” Eur Heart J 28, no. 4 (February 2007): 425–32. https://doi.org/10.1093/eurheartj/ehl483.

PMID
17267458
Full Text

Dyke, Christopher K., Steven R. Steinhubl, Neal S. Kleiman, Richard O. Cannon, Laura G. Aberle, Min Lin, Shelley K. Myles, et al. “First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.” Circulation 114, no. 23 (December 5, 2006): 2490–97. https://doi.org/10.1161/CIRCULATIONAHA.106.668434.

PMID
17101847
Full Text

Pages